Download PDF
Thromb Haemost 2021; 121(12): 1562-1573
DOI: 10.1055/a-1414-5009
Review Article

Pre-Hospital Antiplatelet Therapy for STEMI Patients Undergoing Primary Percutaneous Coronary Intervention: What We Know and What Lies Ahead

Enrico Fabris 
1   Cardiovascular Department, University of Trieste, Trieste, Italy
,
Serge Korjian
2   Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States
,
Barry S. Coller
3   Allen and Frances Adler Laboratory of Blood and Vascular Biology, Rockefeller University, New York, New York, United States
,
Jurrien M. Ten Berg
4   Department of Cardiology, St Antonius Hospital, Nieuwegein, The Netherlands
,
Christopher B. Granger
5   Duke Clinical Research Institute and the Division of Cardiology, Duke University Medical Center, Durham, North Carolina, United States
,
C. Michael Gibson
2   Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States
,
Arnoud W. J. van 't Hof
6   Department of Cardiology, Zuyderland Medical Centre, Heerlen, The Netherlands
7   Department of Cardiology, Maastricht University Medical Centre, Maastricht, The Netherlands
8   Cardiovascular Research Institute Maastricht (CARIM), Maastricht, The Netherlands
› Author Affiliations Funding This work was supported by Grant 19278 from the National Heart, Lung, and Blood Institute and grant UL1 TR001866 from the National Center for Advancing Translational Sciences.
› Further Information
   Permissions and Reprints

Abstract

Early recanalization of the infarct-related artery to achieve myocardial reperfusion is the primary therapeutic goal in patients with ST-elevation myocardial infarction (STEMI). To decrease the duration of ischaemia, continuous efforts have been made to improve pre-hospital treatment and to target the early period after symptom onset. In this period the platelet content of the fresh coronary thrombus is maximal and the thrombi are dynamic, and thus more susceptible to powerful antiplatelet agents. There have been substantial advances in antiplatelet therapy in the last three decades with several classes of oral and intravenous antiplatelet agents with different therapeutic targets, pharmacokinetics, and pharmacodynamic properties. New parenteral drugs achieve immediate inhibition of platelet aggregation, and fast and easy methods of administration may create the opportunity to bridge the initial gap in platelet inhibition observed with oral P2Y12 inhibitors. Moreover, potential future management of STEMI could directly involve patients in the process of care with self-administered antiplatelet agents designed to achieve rapid reperfusion. However, the potential anti-ischaemic benefits of potent antiplatelet agents will need to be balanced against their risk of increased bleeding. This study presents a comprehensive and updated review of pre-hospital antiplatelet therapy among STEMI patients undergoing primary percutaneous intervention and explores new therapies under development.

Keywords

myocardial infarction - STEMI - pre-hospital - coronary reperfusion - antiplatelet therapy - P2Y12 inhibitors - glycoprotein IIb/IIIa - selatogrel - RUC-4


Publication History

Received: 22 December 2020

Accepted: 02 March 2021

Accepted Manuscript online:
07 March 2021

Article published online:
30 April 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 DeWood MA, Spores J, Notske R. et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980; 303 (16) 897-902
    CrossrefPubMedGoogle Scholar
  • 2 Popovic B, Agrinier N, Bouchahda N. et al. Coronary embolism among ST-segment-elevation myocardial infarction patients: mechanisms and management. Circ Cardiovasc Interv 2018; 11 (01) e005587
    CrossrefPubMedGoogle Scholar
  • 3 Ibanez B, James S, Agewall S. et al; ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018; 39 (02) 119-177
    CrossrefPubMedGoogle Scholar
  • 4 Valgimigli M, Bueno H, Byrne RA. et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018; 39 (03) 213-260
    CrossrefPubMedGoogle Scholar
  • 5 Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med 2008; 359 (09) 938-949
    CrossrefPubMedGoogle Scholar
  • 6 Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002; 8 (11) 1227-1234
    CrossrefPubMedGoogle Scholar
  • 7 Davì G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007; 357 (24) 2482-2494
    CrossrefPubMedGoogle Scholar
  • 8 Woodside DG, Liu S, Ginsberg MH. Integrin activation. Thromb Haemost 2001; 86 (01) 316-323
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Silvain J, Collet J-P, Nagaswami C. et al. Composition of coronary thrombus in acute myocardial infarction. J Am Coll Cardiol 2011; 57 (12) 1359-1367
    CrossrefPubMedGoogle Scholar
  • 10 Fabris E, Arrigoni P, Falco L. et al. Impact of patient delay in a modern real world STEMI network. Am J Emerg Med 2020; 38 (06) 1195-1198
    CrossrefPubMedGoogle Scholar
  • 11 Xu Q, Yin J, Si LY. Efficacy and safety of early versus late glycoprotein IIb/IIIa inhibitors for PCI. Int J Cardiol 2013; 162 (03) 210-219
    CrossrefPubMedGoogle Scholar
  • 12 De Luca G, Gibson CM, Bellandi F. et al. Early glycoprotein IIb-IIIa inhibitors in primary angioplasty (EGYPT) cooperation: an individual patient data meta-analysis. Heart 2008; 94 (12) 1548-1558
    CrossrefPubMedGoogle Scholar
  • 13 Gold HK, Garabedian HD, Dinsmore RE. et al. Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators. Observations in animals and humans. Circulation 1997; 95 (07) 1755-1759
    CrossrefPubMedGoogle Scholar
  • 14 Montalescot G, van 't Hof AW, Bolognese L. et al; ATLANTIC Investigators. Effect of pre-hospital ticagrelor during the first 24 h after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction: the ATLANTIC-H24 analysis. JACC Cardiovasc Interv 2016; 9 (07) 646-656
    CrossrefPubMedGoogle Scholar
  • 15 Smit JJJ, van Werkum JW, ten Berg J. et al; Ongoing Tirofiban in Myocardial Infarction Evaluation (On-TIME) trial investigators. Prehospital triple antiplatelet therapy in patients with acute ST elevation myocardial infarction leads to better platelet aggregation inhibition and clinical outcome than dual antiplatelet therapy. Heart 2010; 96 (22) 1815-1820
    CrossrefPubMedGoogle Scholar
  • 16 Jennings LK, Jacoski MV, White MM. The pharmacodynamics of parenteral glycoprotein IIb/IIIa inhibitors. J Interv Cardiol 2002; 15 (01) 45-60
    CrossrefPubMedGoogle Scholar
  • 17 Capranzano P, Angiolillo DJ. Tailoring P2Y12 inhibiting therapy in elderly patients with myocardial infarction undergoing primary percutaneous coronary intervention. J Am Heart Assoc 2019; 8 (18) e014000
    CrossrefPubMedGoogle Scholar
  • 18 Van't Hof AW, Ten Berg J, Heestermans T. et al; Ongoing Tirofiban In Myocardial infarction Evaluation (On-TIME) 2 study group. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial. Lancet 2008; 372 (9638): 537-546
    CrossrefPubMedGoogle Scholar
  • 19 Montalescot G, van 't Hof AW, Lapostolle F. et al; ATLANTIC Investigators. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med 2014; 371 (11) 1016-1027
    CrossrefPubMedGoogle Scholar
  • 20 Bellemain-Appaix A, Bégué C, Bhatt DL. et al. The efficacy of early versus delayed P2Y12 inhibition in percutaneous coronary intervention for ST-elevation myocardial infarction: a systematic review and meta-analysis. EuroIntervention 2018; 14 (01) 78-85
    CrossrefPubMedGoogle Scholar
  • 21 Awtry EH, Loscalzo J. Aspirin. Circulation 2000; 101 (10) 1206-1218
    CrossrefPubMedGoogle Scholar
  • 22 RANDOMISED TRIAL OF INTRAVENOUS STREPTOKINASE. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988; 2 (8607): 349-360
    PubMedGoogle Scholar
  • 23 Sagar KA, Smyth MR. A comparative bioavailability study of different aspirin formulations using on-line multidimensional chromatography. J Pharm Biomed Anal 1999; 21 (02) 383-392
    CrossrefPubMedGoogle Scholar
  • 24 O'Gara PT, Kushner FG, Ascheim DD. et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 61 (04) 485-510
    CrossrefPubMedGoogle Scholar
  • 25 Zeymer U, Hohlfeld T, Vom Dahl J. et al. Prospective, randomised trial of the time dependent antiplatelet effects of 500 mg and 250 mg acetylsalicylic acid i. v. and 300 mg p. o. in ACS (ACUTE). Thromb Haemost 2017; 117 (03) 625-635
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Meadows TA, Bhatt DL. Clinical aspects of platelet inhibitors and thrombus formation. Circ Res 2007; 100 (09) 1261-1275
    CrossrefPubMedGoogle Scholar
  • 27 Capodanno D, Alfonso F, Levine GN, Valgimigli M, Angiolillo DJ. ACC/AHA versus ESC guidelines on dual antiplatelet therapy: JACC guideline comparison. J Am Coll Cardiol 2018; 72 (23, Pt A): 2915-2931
    CrossrefPubMedGoogle Scholar
  • 28 Wiviott SD, Braunwald E, McCabe CH. et al; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357 (20) 2001-2015
    CrossrefPubMedGoogle Scholar
  • 29 Wallentin L, Becker RC, Budaj A. et al; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361 (11) 1045-1057
    CrossrefPubMedGoogle Scholar
  • 30 Claassens DMF, Vos GJA, Bergmeijer TO. et al. A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI. N Engl J Med 2019; 381 (17) 1621-1631
    CrossrefPubMedGoogle Scholar
  • 31 Parodi G, Valenti R, Bellandi B. et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol 2013; 61 (15) 1601-1606
    CrossrefPubMedGoogle Scholar
  • 32 Motovska Z, Hlinomaz O, Miklik R. et al; PRAGUE-18 Study Group. Prasugrel versus ticagrelor in patients with acute myocardial infarction treated with primary percutaneous coronary intervention: multicenter randomized PRAGUE-18 study. Circulation 2016; 134 (21) 1603-1612
    CrossrefPubMedGoogle Scholar
  • 33 Schüpke S, Neumann F-J, Menichelli M. et al; ISAR-REACT 5 Trial Investigators. Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med 2019; 381 (16) 1524-1534
    CrossrefPubMedGoogle Scholar
  • 34 Aytekin A, Ndrepepa G, Neumann F-J. et al. Ticagrelor or prasugrel in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation 2020; 142 (24) 2329-2337
    CrossrefPubMedGoogle Scholar
  • 35 Schulz S, Angiolillo DJ, Antoniucci D. et al; Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 Trial Investigators. Randomized comparison of ticagrelor versus prasugrel in patients with acute coronary syndrome and planned invasive strategy: design and rationale of the iNtracoronary Stenting and Antithrombotic Regimen—Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 trial. J Cardiovasc Transl Res 2014; 7 (01) 91-100
    CrossrefPubMedGoogle Scholar
  • 36 Menichelli M, Neumann F-J, Ndrepepa G. et al. Age- and weight-adapted dose of prasugrel versus standard dose of ticagrelor in patients with acute coronary syndromes: results from a randomized trial. Ann Intern Med 2020; 173 (06) 436-444
    CrossrefPubMedGoogle Scholar
  • 37 Silvain J, Storey RF, Cayla G. et al. P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction. The PRIVATE-ATLANTIC study. Thromb Haemost 2016; 116 (02) 369-378
    Article in Thieme ConnectPubMedGoogle Scholar
  • 38 Hobl E-L, Stimpfl T, Ebner J. et al. Morphine decreases clopidogrel concentrations and effects: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2014; 63 (07) 630-635
    CrossrefPubMedGoogle Scholar
  • 39 Parodi G, Bellandi B, Xanthopoulou I. et al. Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention. Circ Cardiovasc Interv 2014; 8 (01) e001593
    CrossrefPubMedGoogle Scholar
  • 40 Zwart B, Yazdani M, Ow KW. et al. Use of glycoprotein IIb/IIIa antagonists to prevent stent thrombosis in morphine-treated patients with ST-elevation myocardial infarction. Platelets 2020; 31 (02) 174-178
    CrossrefPubMedGoogle Scholar
  • 41 Lev EI, Kornowski R, Vaknin-Assa H. et al. Effect of clopidogrel pretreatment on angiographic and clinical outcomes in patients undergoing primary percutaneous coronary intervention for ST-elevation acute myocardial infarction. Am J Cardiol 2008; 101 (04) 435-439
    CrossrefPubMedGoogle Scholar
  • 42 Fefer P, Hod H, Hammerman H. et al. Usefulness of pretreatment with high-dose clopidogrel in patients undergoing primary angioplasty for ST-elevation myocardial infarction. Am J Cardiol 2009; 104 (04) 514-518
    CrossrefPubMedGoogle Scholar
  • 43 Larson DM, Duval S, Sharkey SS. et al. Clopidogrel pretreatment in ST-elevation myocardial infarction patients transferred for percutaneous coronary intervention. Am Heart J 2010; 160 (01) 202-207
    CrossrefPubMedGoogle Scholar
  • 44 Dörler J, Edlinger M, Alber HF. et al; Austrian Acute PCI Investigators. Clopidogrel pre-treatment is associated with reduced in-hospital mortality in primary percutaneous coronary intervention for acute ST-elevation myocardial infarction. Eur Heart J 2011; 32 (23) 2954-2961
    CrossrefPubMedGoogle Scholar
  • 45 Bellemain-Appaix A, O'Connor SA, Silvain J. et al; ACTION Group. Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. JAMA 2012; 308 (23) 2507-2516
    CrossrefPubMedGoogle Scholar
  • 46 Ducci K, Grotti S, Falsini G. et al. Comparison of pre-hospital 600 mg or 900 mg vs. peri-interventional 300 mg clopidogrel in patients with ST-elevation myocardial infarction undergoing primary coronary angioplasty. The Load&Go randomized trial. Int J Cardiol 2013; 168 (05) 4814-4816
    CrossrefPubMedGoogle Scholar
  • 47 Zeymer U, Arntz H-R, Mark B. et al. Efficacy and safety of a high loading dose of clopidogrel administered prehospitally to improve primary percutaneous coronary intervention in acute myocardial infarction: the randomized CIPAMI trial. Clin Res Cardiol 2012; 101 (04) 305-312
    CrossrefPubMedGoogle Scholar
  • 48 Krumholz HM, Herrin J, Miller LE. et al. Improvements in door-to-balloon time in the United States, 2005 to 2010. Circulation 2011; 124 (09) 1038-1045
    CrossrefPubMedGoogle Scholar
  • 49 Wang TY, Nallamothu BK, Krumholz HM. et al. Association of door-in to door-out time with reperfusion delays and outcomes among patients transferred for primary percutaneous coronary intervention. JAMA 2011; 305 (24) 2540-2547
    CrossrefPubMedGoogle Scholar
  • 50 Fabris E, Van't Hof A, Hamm CW. et al. Impact of presentation and transfer delays on complete ST-segment resolution before primary percutaneous coronary intervention: insights from the ATLANTIC trial. EuroIntervention 2017; 13 (01) 69-77
    CrossrefPubMedGoogle Scholar
  • 51 Danchin N, Puymirat E, Cayla G. et al; FAST-MI Investigators. One-year survival after ST-segment-elevation myocardial infarction in relation with prehospital administration of dual antiplatelet therapy. Circ Cardiovasc Interv 2018; 11 (09) e007241
    CrossrefPubMedGoogle Scholar
  • 52 Redfors B, Dworeck C, Haraldsson I. et al. Pretreatment with P2Y12 receptor antagonists in ST-elevation myocardial infarction: a report from the Swedish Coronary Angiography and Angioplasty Registry. Eur Heart J 2019; 40 (15) 1202-1210
    CrossrefPubMedGoogle Scholar
  • 53 Venetsanos D, Sederholm Lawesson S, Swahn E, Alfredsson J. Chewed ticagrelor tablets provide faster platelet inhibition compared to integral tablets: the inhibition of platelet aggregation after administration of three different ticagrelor formulations (IPAAD-Tica) study, a randomised controlled trial. Thromb Res 2017; 149: 88-94
    CrossrefPubMedGoogle Scholar
  • 54 Alexopoulos D, Barampoutis N, Gkizas V. et al. Crushed versus integral tablets of ticagrelor in ST-segment elevation myocardial infarction patients: a randomized pharmacokinetic/pharmacodynamic study. Clin Pharmacokinet 2016; 55 (03) 359-367
    CrossrefPubMedGoogle Scholar
  • 55 Rollini F, Franchi F, Hu J. et al. Crushed prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary intervention: the CRUSH study. J Am Coll Cardiol 2016; 67 (17) 1994-2004
    CrossrefPubMedGoogle Scholar
  • 56 Vlachojannis GJ, Wilschut JM, Vogel RF. et al. Effect of prehospital crushed prasugrel tablets in patients with ST-segment-elevation myocardial infarction planned for primary percutaneous coronary intervention: the randomized COMPARE CRUSH trial. Circulation 2020; 142 (24) 2316-2328
    CrossrefPubMedGoogle Scholar
  • 57 Karathanos A, Lin Y, Dannenberg L. et al. Routine glycoprotein IIb/IIIa inhibitor therapy in ST-segment elevation myocardial infarction: a meta-analysis. Can J Cardiol 2019; 35 (11) 1576-1588
    CrossrefPubMedGoogle Scholar
  • 58 Investigators E. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330 (14) 956-961
    CrossrefPubMedGoogle Scholar
  • 59 Investigators E. EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336 (24) 1689-1696
    CrossrefPubMedGoogle Scholar
  • 60 Investigators E. EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998; 352 (9122): 87-92
    CrossrefPubMedGoogle Scholar
  • 61 Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 1997; 349 (9063): 1429-1435
    CrossrefPubMedGoogle Scholar
  • 62 Gabriel HM, Oliveira JA, da Silva PC, da Costa JM, da Cunha JA. Early administration of abciximab bolus in the emergency department improves angiographic outcome after primary PCI as assessed by TIMI frame count: results of the early ReoPro administration in myocardial infarction (ERAMI) trial. Catheter Cardiovasc Interv 2006; 68 (02) 218-224
    CrossrefPubMedGoogle Scholar
  • 63 Maioli M, Bellandi F, Leoncini M, Toso A, Dabizzi RP. Randomized early versus late abciximab in acute myocardial infarction treated with primary coronary intervention (RELAx-AMI Trial). J Am Coll Cardiol 2007; 49 (14) 1517-1524
    CrossrefPubMedGoogle Scholar
  • 64 Siudak Z, Rakowski T, Dziewierz A. et al. Early abciximab use in ST-elevation myocardial infarction treated with primary percutaneous coronary intervention improves long-term outcome. Data from EUROTRANSFER Registry. Kardiol Pol 2010; 68 (05) 539-543
    PubMedGoogle Scholar
  • 65 Montalescot G, Barragan P, Wittenberg O. et al; ADMIRAL Investigators. Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long-Term Follow-up. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001; 344 (25) 1895-1903
    CrossrefPubMedGoogle Scholar
  • 66 Arntz H-R, Schröder JF, Pels K. et al. Prehospital versus periprocedural administration of abciximab in STEMI: early and late results from the randomised REOMOBILE-study. Eur Heart J 2003; 24 (supp 1): 268
    CrossrefPubMedGoogle Scholar
  • 67 Ohlmann P, Reydel P, Jacquemin L. et al. Prehospital abciximab in ST-segment elevation myocardial infarction: results of the randomized, double-blind MISTRAL study. Circ Cardiovasc Interv 2012; 5 (01) 69-76 , S1
    CrossrefPubMedGoogle Scholar
  • 68 Hassan AK, Jukema JW, van der Laarse A. et al. Incidence, patient characteristics and predictors of aborted myocardial infarction in patients undergoing primary PCI: prospective study comparing pre- and in-hospital abciximab pretreatment. EuroIntervention 2009; 4 (05) 662-668
    CrossrefPubMedGoogle Scholar
  • 69 Rakowski T, Zalewski J, Legutko J. et al. Early abciximab administration before primary percutaneous coronary intervention improves infarct-related artery patency and left ventricular function in high-risk patients with anterior wall myocardial infarction: a randomized study. Am Heart J 2007; 153 (03) 360-365
    CrossrefPubMedGoogle Scholar
  • 70 Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998; 339 (07) 436-443
    CrossrefPubMedGoogle Scholar
  • 71 Zeymer U, Zahn R, Schiele R. et al. Early eptifibatide improves TIMI 3 patency before primary percutaneous coronary intervention for acute ST elevation myocardial infarction: results of the randomized integrilin in acute myocardial infarction (INTAMI) pilot trial. Eur Heart J 2005; 26 (19) 1971-1977
    CrossrefPubMedGoogle Scholar
  • 72 Gibson CM, Kirtane AJ, Murphy SA. et al; TIMI Study Group. Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 trial. Am Heart J 2006; 152 (04) 668-675
    CrossrefPubMedGoogle Scholar
  • 73 Hanefeld C, Sirtl C, Spiecker M. et al. Prehospital therapy with the platelet glycoprotein IIb/IIIa inhibitor eptifibatide in patients with suspected acute coronary syndromes: the Bochum feasibility study. Chest 2004; 126 (03) 935-941
    CrossrefPubMedGoogle Scholar
  • 74 Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998; 338 (21) 1488-1497
    CrossrefPubMedGoogle Scholar
  • 75 Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998; 338 (21) 1498-1505
    CrossrefPubMedGoogle Scholar
  • 76 Valgimigli M, Percoco G, Malagutti P. et al; STRATEGY Investigators. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA 2005; 293 (17) 2109-2117
    CrossrefPubMedGoogle Scholar
  • 77 Cutlip DE, Ricciardi MJ, Ling FS. et al. Effect of tirofiban before primary angioplasty on initial coronary flow and early ST-segment resolution in patients with acute myocardial infarction. Am J Cardiol 2003; 92 (08) 977-980
    CrossrefPubMedGoogle Scholar
  • 78 ten Berg JM, van 't Hof AW, Dill T. et al; On-TIME 2 Study Group. Effect of early, pre-hospital initiation of high bolus dose tirofiban in patients with ST-segment elevation myocardial infarction on short- and long-term clinical outcome. J Am Coll Cardiol 2010; 55 (22) 2446-2455
    CrossrefPubMedGoogle Scholar
  • 79 Hermanides RS, van Werkum JW, Ottervanger JP. et al; Ongoing Tirofiban In Myocardial infarction Evaluation (On-TIME) 2 study group. The effect of pre-hospital glycoprotein IIb-IIIa inhibitors on angiographic outcome in STEMI patients who are candidates for primary PCI. Catheter Cardiovasc Interv 2012; 79 (06) 956-964
    CrossrefPubMedGoogle Scholar
  • 80 Fabris E, Ottervanger JP, Hermanides RS. et al. Effect of early tirofiban administration on N-terminal pro-B-type natriuretic peptide level in patients treated with primary percutaneous coronary intervention. Catheter Cardiovasc Interv 2019; 93 (05) E293-E297
    CrossrefPubMedGoogle Scholar
  • 81 Fabris E, Kilic S, Schellings DAAM. et al. Long-term mortality and prehospital tirofiban treatment in patients with ST elevation myocardial infarction. Heart 2017; 103 (19) 1515-1520
    CrossrefPubMedGoogle Scholar
  • 82 Akers WS, Oh JJ, Oestreich JH, Ferraris S, Wethington M, Steinhubl SR. Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y12 receptor antagonist. J Clin Pharmacol 2010; 50 (01) 27-35
    CrossrefPubMedGoogle Scholar
  • 83 Steg PG, Bhatt DL, Hamm CW. et al; CHAMPION Investigators. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet 2013; 382 (9909): 1981-1992
    CrossrefPubMedGoogle Scholar
  • 84 Steinhubl SR, Oh JJ, Oestreich JH, Ferraris S, Charnigo R, Akers WS. Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thromb Res 2008; 121 (04) 527-534
    CrossrefPubMedGoogle Scholar
  • 85 Franchi F, Rollini F, Rivas A. et al. platelet inhibition with cangrelor and crushed ticagrelor in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation 2019; 139 (14) 1661-1670
    CrossrefPubMedGoogle Scholar
  • 86 Alexopoulos D, Pappas C, Sfantou D. et al. Cangrelor in ticagrelor-loaded STEMI patients undergoing primary percutaneous coronary intervention. J Am Coll Cardiol 2018; 72 (14) 1750-1751
    CrossrefPubMedGoogle Scholar
  • 87 Gargiulo G, Esposito G, Avvedimento M. et al. Cangrelor, tirofiban, and chewed or standard prasugrel regimens in patients with ST-segment-elevation myocardial infarction: primary results of the FABOLUS-FASTER trial. Circulation 2020; 142 (05) 441-454
    CrossrefPubMedGoogle Scholar
  • 88 Milluzzo RP, Franchina GA, Capodanno D, Angiolillo DJ. Selatogrel, a novel P2Y12 inhibitor: a review of the pharmacology and clinical development. Expert Opin Investig Drugs 2020; 29 (06) 537-546
    CrossrefPubMedGoogle Scholar
  • 89 Storey RF, Gurbel PA, Ten Berg J. et al. Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes. Eur Heart J 2020; 41 (33) 3132-3140
    CrossrefPubMedGoogle Scholar
  • 90 Sinnaeve P, Fahrni G, Schelfaut D. et al. Subcutaneous selatogrel inhibits platelet aggregation in patients with acute myocardial infarction. J Am Coll Cardiol 2020; 75 (20) 2588-2597
    CrossrefPubMedGoogle Scholar
  • 91 Li J, Vootukuri S, Shang Y. et al. RUC-4: a novel αIIbβ3 antagonist for prehospital therapy of myocardial infarction. Arterioscler Thromb Vasc Biol 2014; 34 (10) 2321-2329
    CrossrefPubMedGoogle Scholar
  • 92 Late-Breaking Science Abstracts and Featured Science Abstracts From the American Heart Association's Scientific Sessions 2019 and Late-Breaking Abstracts in Resuscitation Science From the Resuscitation Science Symposium 2019. Circulation 2019; 140 (25) e965-e1011
    CrossrefPubMedGoogle Scholar
  • 93 Schüpke S, Hein-Rothweiler R, Mayer K. et al; ISAR-PLASTER-Trial Investigators. Revacept, a novel inhibitor of platelet adhesion, in patients undergoing elective PCI-design and rationale of the randomized ISAR-PLASTER trial. Thromb Haemost 2019; 119 (09) 1539-1545
    Article in Thieme ConnectPubMedGoogle Scholar
  • 94 Gilbert JC, DeFeo-Fraulini T, Hutabarat RM. et al. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation 2007; 116 (23) 2678-2686
    CrossrefPubMedGoogle Scholar
  • 95 Ziegler M, Wang X, Peter K. Platelets in cardiac ischaemia/reperfusion injury: a promising therapeutic target. Cardiovasc Res 2019; 115 (07) 1178-1188
    CrossrefPubMedGoogle Scholar
  • 96 Gibson CM, Holmes D, Mikdadi G. et al. Implantable cardiac alert system for early recognition of ST-segment elevation myocardial infarction. J Am Coll Cardiol 2019; 73 (15) 1919-1927
    CrossrefPubMedGoogle Scholar